NCT02230761View on ClinicalTrials.gov

Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Interventions
DRUG

XOPH5 Ointment

DRUG

Placebo

Trial Locations (1)

02111

Topokine Therapeutics Clinical Study Centers, Boston

All Listed Sponsors
lead

Topokine Therapeutics, Inc.

INDUSTRY

NCT02230761 - Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon) | Biotech Hunter | Biotech Hunter